Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hubert Hertenberger is active.

Publication


Featured researches published by Hubert Hertenberger.


mAbs | 2013

Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies

Tilman Schlothauer; Petra Rueger; Jan Olaf Stracke; Hubert Hertenberger; Felix Fingas; Lothar Kling; Thomas Emrich; Georg Drabner; Stefan Seeber; Johannes Auer; Stefan Koch; Apollon Papadimitriou

The neonatal Fc receptor (FcRn) is important for the metabolic fate of IgG antibodies in vivo. Analysis of the interaction between FcRn and IgG in vitro might provide insight into the structural and functional integrity of therapeutic IgG that may affect pharmacokinetics (PK) in vivo. We developed a standardized pH gradient FcRn affinity liquid chromatography method with conditions closely resembling the physiological mechanism of interaction between IgG and FcRn. This method allows the separation of molecular IgG isoforms, degradation products and engineered molecules based on their affinity to FcRn. Human FcRn was immobilized on the column and a linear pH gradient from pH 5.5 to 8.8 was applied. FcRn chromatography was used in comparison to surface plasmon resonance to characterize different monoclonal IgG preparations, e.g., oxidized or aggregated species. Wild-type and engineered IgGs were compared in vitro by FcRn chromatography and in vivo by PK studies in huFcRn transgenic mice. Analytical FcRn chromatography allows differentiation of IgG samples and variants by peak pattern and retention time profile. The method can distinguish: 1) IgGs with different Fabs, 2) oxidized from native IgG, 3) aggregates from monomer and 4) antibodies with mutations in the Fc part from wild-type IgGs. Changes in the FcRn chromatographic behavior of mutant IgGs relative to the wild-type IgG correlate to changes in the PK profile in the FcRn transgenic mice. These results demonstrate that FcRn affinity chromatography is a useful new method for the assessment of IgG integrity.


mAbs | 2014

A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies

Jan Olaf Stracke; Thomas Emrich; Petra Rueger; Tilman Schlothauer; Lothar Kling; Alexander Knaupp; Hubert Hertenberger; Andreas Wolfert; Christian Spick; Wilma Lau; Georg Drabner; Ulrike Reiff; Hans Koll; Apollon Papadimitriou

Preserving the chemical and structural integrity of therapeutic antibodies during manufacturing and storage is a major challenge during pharmaceutical development. Oxidation of Fc methionines Met252 and Met428 is frequently observed, which leads to reduced affinity to FcRn and faster plasma clearance if present at high levels. Because oxidation occurs in both positions simultaneously, their individual contribution to the concomitant changes in pharmacokinetic properties has not been clearly established. A novel pH-gradient FcRn affinity chromatography method was applied to isolate three antibody oxidation variants from an oxidized IgG1 preparation based on their FcRn binding properties. Physico-chemical characterization revealed that the three oxidation variants differed predominantly in the number of oxMet252 per IgG (0, 1, or 2), but not significantly in the content of oxMet428. Corresponding to the increase in oxMet252 content, stepwise reduction of FcRn affinity in vitro, as well as faster clearance and shorter terminal half-life, in huFcRn-transgenic mice were observed. A single Met252 oxidation per antibody had no significant effect on pharmacokinetics (PK) compared with unmodified IgG. Importantly, only molecules with both heavy chains oxidized at Met252 exhibited significantly faster clearance. In contrast, Met428 oxidation had no apparent negative effect on PK and even led to somewhat improved FcRn binding and slower clearance. This minor effect, however, seemed to be abrogated by the dominant effect of Met252 oxidation. The novel approach of functional chromatographic separation of IgG oxidation variants followed by physico-chemical and biological characterization has yielded the first experimentally-backed explanation for the unaltered PK properties of antibody preparations containing relatively high Met252 and Met428 oxidation levels.


Archive | 2006

Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer Agents

Richard A. Engh; Hubert Hertenberger; Konrad Honold; Birgit Masjost; Petra Rueger; Wolfgang Schaefer; Stefan Scheiblich; Manfred Schwaiger


Archive | 2005

Amide Derivatives of 7-Amino-3-Phenyl-Dihydropyrimido[4,5-D]Pyrimidinones, Their Manufacture and Use as Pharmaceutical Agents

Richard A. Engh; Hubert Hertenberger; Konrad Honold; Birgit Masjost; Petra Rueger; Wolfgang Schaefer; Stefan Scheiblich; Manfred Schwaiger


Archive | 2013

FC-RECEPTOR BASED AFFINITY CHROMATOGRAPHY

Roberto Falkenstein; Hubert Hertenberger; Petra Rueger; Tilman Schlothauer


Archive | 2004

Method for the recombinant production and purification of protein kinases

Hubert Hertenberger; Konrad Honold; Christian Klein; Petra Rueger


Archive | 2013

Chromatographie d'affinité faisant appel à des récepteurs fc

Roberto Falkenstein; Hubert Hertenberger; Petra Rueger; Tilman Schlothauer


Archive | 2006

Derives de l'azabenzimidazole, leur fabrication et leur utilisation en tant qu'agents anticancereux

Richard A. Engh; Hubert Hertenberger; Konrad Honold; Birgit Masjost; Petra Rueger; Wolfgang Schaefer; Stefan Scheiblich; Manfred Schwaiger


Archive | 2006

Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel Azabenzimidalzolderivate, their preparation and their use as anticancer agents

Richard A. Engh; Hubert Hertenberger; Konrad Honold; Birgit Masjost; Petra Rueger; Wolfgang Schaefer; Stefan Scheiblich; Manfred Schwaiger


Archive | 2005

düpyrimidinonen 3-phenyldihydropyrimidoä4,5-amide derivatives of, their preparation and use as pharmaceutical agents

Richard A. Engh; Hubert Hertenberger; Konrad Honold; Birgit Masjost; Petra Rueger; Wolfgang Schaefer; Stefan Scheiblich; Manfred Schwaiger

Collaboration


Dive into the Hubert Hertenberger's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge